Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of LASN01 in Thyroid Eye Disease (Graves' ophthalmopathy) has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy
• Thyroid Eye Disease

Drugs mentioned

• LASN01

Snippet

Sponsor: Lassen Therapeutics Inc. | Conditions: Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Status: COMPLETED | Results posted: 2026-03-09